He Shoots And He Scores. Ardelyx (ARDX) Gains 78%. Happy New Year!
Ah yes, and Gains Come to the Patient, as the FDA Moves the Ardelyx Ball Further Along.
Ardelyx (ARDX). Don’t be Nervous, It’s Just Money.
The Higher it Goes, The More Nervous we Get.
LIVE QUOTE
Adding Unicycive (UNCY) $0.75 to the Watch List.
Similar to Ardlyx (ARDX) which we added to the Watch List last week, Unicycive (no we don't know how they pronounce it) which will call UNCY - is...
FDA Approval for Provention Bio (PRVB).
Re-cork the Champagne!
We were contemplating (dreaming) about an opening price over $12, and then a drift up...
Adding Ardelyx (ARDX) $1.57 to Watch List.
FDA Advisory Committee Says Go Forth Young Man!
While we hadn't previously owned Ardelyx, nor are they a...
Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital
Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval....
Adding Provention Bio (PRVB) $4.60 to 2022 Biotech Watch List.
This is in our 'Stocks we Hope to Double' Watch List.
LIVE QUOTE
Provention (PRVB) Price Target $18.
Headline Says Downgrade, But That's Near 300% Higher From Here!
LIVE QUOTE
Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.
Here's How Provention's Treatment Works.
Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)
Teplizumab: Can We Delay the Onset of Type 1?
Last updated: 6/7/21
By Dr. Francine...
Latest article
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
